Ventyx Biosciences

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in Encinitas, CA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Ventyx Biosciences reports Q1 losses, eyes market growth opportunities

Ventyx Biosciences navigates financial challenges with strong pipeline progress and strategic cash reserves.
Confidence in drug efficacy and proactive commercial planning position the company for market success.
Challenges from market competition and strategic decisions are balanced by growth opportunities and diversification.
Engagement with stakeholders and ongoing program advancements drive optimism for future growth and development.

Ventyx Biosciences progresses in Phase II trials amid commercial challenges

Ventyx Biosciences shows promising progress in Phase II trials for VTX958 and VTX002, with a focus on immune diseases like ulcerative colitis and psoriasis.
Challenges in commercial performance and trial diversity persist, but opportunities lie in upcoming Phase II results and potential expansion into new indications.
The company's financial performance reflects increased R&D investment, while strategic decisions on drug development and market positioning are crucial for future success.
Overall, Ventyx's innovative therapies and perseverance in trials position it for growth, pending successful Phase II outcomes and strategic adaptations.

Ventyx Biosciences reports promising Q1 results, eyes strategic partnerships

Ventyx Biosciences showcased strong performance in key inhibitors and IBD assets, despite facing financial challenges and the need to navigate regulatory complexities. The company's focus on innovation, upcoming trials, and potential partnerships positions them well for future growth and success in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.